PC
KYNB

Polar Capital’s Kyntra Bio KYNB Stock Holding History

Polar Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-651
Closed -$383K – 277
2015
Q2 		$383K Buy
651
+319
+96% +$186K 0.01% 274
2015
Q1 		$260K Buy
+332
New +$257K ﹤0.01% 278

Other funds holding KYNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Polar Capital's KYNB Position: Q3 2015 in Review

Polar Capital sold out of Kyntra Bio (KYNB) in Q3 2015, closing a stake of 651 shares — an estimated $383K sold.

Polar Capital first reported a position in KYNB in Q1 2015 and held it in 2 quarters. The position peaked at $383K in Q2 2015. 118 funds tracked by Wall St. Rank hold KYNB as of Q3 2015.

  • Polar Capital reported no remaining Kyntra Bio position as of Q3 2015 after selling out during the quarter.
  • Polar Capital sold 651 Kyntra Bio shares in Q3 2015, an estimated $383K.
  • Polar Capital first reported a position in Kyntra Bio in Q1 2015 and held it in 2 quarters.
  • Polar Capital's Kyntra Bio position peaked at $383K in Q2 2015.
  • 118 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2015.

Based on Polar Capital's 13F filing for Q3 2015, filed 16 Nov 2015.